{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:52:20Z","timestamp":1762429940302,"version":"3.37.3"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH Specialized Program in Research Excellence","doi-asserted-by":"publisher","award":["CA 88843"],"award-info":[{"award-number":["CA 88843"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:<\/jats:p>\n                  <jats:p>Discuss the pros and cons of various methods of ovarian ablation, including oophorectomy, radiation therapy, and luteinizing hormone releasing hormone (LHRH) analogues. Recall the frequency of chemotherapy-related amenorrhea with commonly used regimens in adjuvant breast cancer treatment. Discuss the evidence supporting the use of ovarian ablation in premenopausal women with early-stage breast cancer. Discuss the evidence supporting the use of ovarian ablation in premenopausal women with locally advanced and metastatic breast cancer.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p>\n                  <jats:p>Ovarian ablation has been used for more than a century in the treatment of breast cancer. Methods of irreversible ovarian ablation include surgical oophorectomy and ovarian irradiation. Potentially reversible castration can be accomplished medically using luteinizing hormone releasing hormone (LHRH) analogues. In addition, cytotoxic chemotherapy unpredictably produces amenorrhea and primary ovarian failure in 10%\u201395% of premenopausal women as a function of patient age, cumulative dose, and the specific agents used. In the metastatic setting, ovarian ablation and tamoxifen monotherapies produce comparable outcomes and may be more effective when used together. While many early adjuvant trials of ovarian ablation were methodologically flawed, a more recent meta-analysis by the Early Breast Cancer Trialists\u2019 Collaborative Group of 12 properly designed randomized trials found significantly greater disease-free and overall survival rates for women under the age of 50, regardless of nodal status, receiving ovarian ablation as a single adjuvant therapy. Several important issues regarding the role of ovarian ablation in the treatment of breast cancer remain unresolved. Data suggest that ovarian ablation followed by some years of tamoxifen produces similar results to those seen with adjuvant chemotherapy in women with hormone-receptor positive breast cancer; however, the value of combining these modalities is still unclear. Other areas of ongoing investigation include the appropriate duration of therapy with LHRH analogues in the adjuvant setting, the long-term sequelae of ovarian suppression among young breast cancer survivors, and refinement of the population most likely to benefit from ovarian ablation or suppression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.9-5-507","type":"journal-article","created":{"date-parts":[[2004,10,11]],"date-time":"2004-10-11T22:42:42Z","timestamp":1097534562000},"page":"507-517","source":"Crossref","is-referenced-by-count":28,"title":["What Is the Role of Ovarian Ablation in the Management of Primary and Metastatic Breast Cancer Today?"],"prefix":"10.1093","volume":"9","author":[{"given":"Tatiana M.","family":"Prowell","sequence":"first","affiliation":[{"name":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy E.","family":"Davidson","sequence":"additional","affiliation":[{"name":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,9,1]]},"reference":[{"key":"2021122209455718400_R1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.1986.4.2.178","article-title":"Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer","volume":"4","author":"Ingle","year":"1986","journal-title":"J Clin Oncol"},{"key":"2021122209455718400_R2","first-page":"569","article-title":"Oophorectomy for advanced carcinoma of the breast","volume":"141","author":"Veronesi","year":"1975","journal-title":"Surg Gynecol Obstet"},{"key":"2021122209455718400_R3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/1097-0142(19890701)64:1<150::AID-CNCR2820640125>3.0.CO;2-N","article-title":"Therapeutic oophorectomy in metastatic breast cancer","volume":"64","author":"Conte","year":"1989","journal-title":"Cancer"},{"key":"2021122209455718400_R4","first-page":"39","article-title":"Clinical response and survival according to estrogen receptor levels after bilateral ovariectomy in advanced breast cancer","volume":"15","author":"Oriana","year":"1989","journal-title":"Eur J Surg Oncol"},{"key":"2021122209455718400_R5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","article-title":"On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases","volume":"2","author":"Beatson","year":"1896","journal-title":"Lancet"},{"key":"2021122209455718400_R6","first-page":"227","article-title":"An analysis of 99 cases of inoperable carcinoma of the breast treated by oophorectomy","volume":"i","author":"Lett","year":"1905","journal-title":"Lancet"},{"key":"2021122209455718400_R7","first-page":"95","article-title":"Ovarian ablation as treatment for young women with breast cancer","volume":"16","author":"Davidson","year":"1994","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2021122209455718400_R8","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.1999.17.8.2365","article-title":"Risk of menopause during the first year after breast cancer diagnosis","volume":"17","author":"Goodwin","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122209455718400_R9","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/bmj.317.7167.1246","article-title":"Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review","volume":"317","author":"Clarke","year":"1998","journal-title":"BMJ"},{"key":"2021122209455718400_R10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(96)05023-4","article-title":"Ovarian ablation in early breast cancer: overview of the randomised trials","volume":"348","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1996","journal-title":"Lancet"},{"key":"2021122209455718400_R11","first-page":"721","article-title":"Oophorectomy versus radiation ablation of ovarian function in patients with metastatic carcinoma of the breast","volume":"151","author":"Lees","year":"1980","journal-title":"Surg Gynecol Obstet"},{"key":"2021122209455718400_R12","first-page":"151","article-title":"Ovarian suppression and its supplement by additive hormonal treatment","volume":"55","author":"Nissen-Meyer","year":"1975","journal-title":"INSERM"},{"key":"2021122209455718400_R13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1259\/0007-1285-64-762-537","article-title":"Ovarian ablation failures by radiation: a comparison of two dose schedules","volume":"64","author":"Leung","year":"1991","journal-title":"Br J Radiol"},{"key":"2021122209455718400_R14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0093-7754(01)90126-5","article-title":"Ovarian ablation as adjuvant therapy for breast cancer","volume":"28","author":"Dees","year":"2001","journal-title":"Semin Oncol"},{"key":"2021122209455718400_R15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/13543784.10.4.709","article-title":"LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action","volume":"10","author":"Limonta","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"2021122209455718400_R16","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1200\/JCO.1985.3.8.1068","article-title":"Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer","volume":"3","author":"Harvey","year":"1985","journal-title":"J Clin Oncol"},{"key":"2021122209455718400_R17","first-page":"244","article-title":"Breast cancer and pregnancy","volume":"50","author":"Donegal","year":"1977","journal-title":"Obstet Gynecol"},{"key":"2021122209455718400_R18","first-page":"125","article-title":"Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects","volume":"16","author":"Reichman","year":"1994","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2021122209455718400_R19","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","article-title":"Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer","volume":"14","author":"Bines","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122209455718400_R20","first-page":"486S","article-title":"Adjuvant hormonal therapy for premenopausal women with breast cancer","volume":"9","author":"Emens","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122209455718400_R21","article-title":"Age-associated incidence of chemotherapy-related amenorrhea (CRA) following adjuvant doxorubicin, cyclophosphamide, and paclitaxel (AC\/TAXOL) in early-stage breast cancer","volume-title":"Proc Am Soc Clin Oncol","author":"Ball","year":"2001"},{"key":"2021122209455718400_R22","first-page":"45","article-title":"Amenorrhea following chemotherapy for breast cancer: effect on disease-free survival","volume":"8","author":"Collichio","year":"1994","journal-title":"Oncology (Huntingt)"},{"key":"2021122209455718400_R23","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","article-title":"Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study","volume":"20","author":"Jonat","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209455718400_R24","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1998.16.3.994","article-title":"Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study","volume":"16","author":"Taylor","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209455718400_R25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/oxfordjournals.annonc.a058837","article-title":"Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study","volume":"5","author":"Boccardo","year":"1994","journal-title":"Ann Oncol"},{"key":"2021122209455718400_R26","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2002.09.112","article-title":"Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer\u2014Austrian Breast and Colorectal Cancer Study Group Trial 5","volume":"20","author":"Jakesz","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209455718400_R27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0959-8049(02)00810-9","article-title":"The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women","volume":"39","author":"Robertson","year":"2003","journal-title":"Eur J Cancer"},{"key":"2021122209455718400_R28","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U","article-title":"The value of estrogen and progesterone receptors in the treatment of breast cancer","volume":"46","author":"Osborne","year":"1980","journal-title":"Cancer"},{"key":"2021122209455718400_R29","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.1984.2.10.1102","article-title":"Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer","volume":"2","author":"Clark","year":"1984","journal-title":"J Clin Oncol"},{"key":"2021122209455718400_R30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1210\/edrv-11-2-221","article-title":"Endocrine treatment of breast cancer in women","volume":"11","author":"Santen","year":"1990","journal-title":"Endocr Rev"},{"key":"2021122209455718400_R31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0305-7372(88)90008-4","article-title":"The clinical biology of hormone-responsive breast cancer","volume":"15","author":"Epstein","year":"1988","journal-title":"Cancer Treat Rev"},{"key":"2021122209455718400_R32","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1002\/1097-0142(20000615)88:12+<3065::AID-CNCR25>3.0.CO;2-P","article-title":"Current and future directions in medical therapy for breast carcinoma: endocrine treatment","volume":"88","author":"Pritchard","year":"2000","journal-title":"Cancer"},{"key":"2021122209455718400_R33","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/0959-8049(93)90031-A","article-title":"Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer","volume":"29A","author":"Blamey","year":"1993","journal-title":"Eur J Cancer"},{"key":"2021122209455718400_R34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/0959-8049(92)90120-Q","article-title":"Goserelin depot in the treatment of premenopausal advanced breast cancer","volume":"28A","author":"Blamey","year":"1992","journal-title":"Eur J Cancer"},{"key":"2021122209455718400_R35","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1200\/JCO.1986.4.9.1326","article-title":"A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer","volume":"4","author":"Buchanan","year":"1986","journal-title":"J Clin Oncol"},{"key":"2021122209455718400_R36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1005895813401","article-title":"A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1","volume":"44","author":"Sawka","year":"1997","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209455718400_R37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/A:1005833811584","article-title":"An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer","volume":"44","author":"Crump","year":"1997","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209455718400_R38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0959-8049(94)00415-2","article-title":"A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer","volume":"31A","author":"Jonat","year":"1995","journal-title":"Eur J Cancer"},{"key":"2021122209455718400_R39","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/92.11.903","article-title":"Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study","volume":"92","author":"Klijn","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2021122209455718400_R40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","article-title":"Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials","volume":"19","author":"Klijn","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209455718400_R41","first-page":"149","article-title":"Estrogen-replacement therapy in younger women with breast cancer","volume":"16","author":"Theriault","year":"1994","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2021122209455718400_R42","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<698::AID-CNCR10>3.0.CO;2-N","article-title":"Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause","volume":"83","author":"Pujol","year":"1998","journal-title":"Cancer"},{"key":"2021122209455718400_R43","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer: an overview of the randomised trials","volume":"352","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1998","journal-title":"Lancet"},{"key":"2021122209455718400_R44","first-page":"1293","article-title":"Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial","volume":"341","author":"Scottish Cancer Trials Breast Group, ICRF Breast Unit, Guy's Hospital, London","year":"1993","journal-title":"Lancet"},{"key":"2021122209455718400_R45","first-page":"2325","article-title":"Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate)","volume":"22","author":"Schmid","year":"2002","journal-title":"Anticancer Res"},{"key":"2021122209455718400_R46","first-page":"66a","article-title":"Comparable effect of ovarian ablation and CMF chemotherapy on premenopausal hormone receptor positive breast cancer patients","volume":"18","author":"Ejlertsen","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209455718400_R47","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/bjc.1996.632","article-title":"Breast carcinomas occurring in young women (&lt;35 years) are different","volume":"74","author":"Walker","year":"1996","journal-title":"Br J Cancer"},{"key":"2021122209455718400_R48","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/bjc.1997.223","article-title":"Early-onset breast cancer\u2014histopathological and prognostic considerations","volume":"75","author":"Kollias","year":"1997","journal-title":"Br J Cancer"},{"key":"2021122209455718400_R49","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(00)02292-3","article-title":"Is chemotherapy alone adequate for young women with oestrogen-receptorpositive breast cancer?","volume":"355","author":"Aebi","year":"2000","journal-title":"Lancet"},{"key":"2021122209455718400_R50","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM198608283150906","article-title":"The relation between survival and age at diagnosis in breast cancer","volume":"315","author":"Adami","year":"1986","journal-title":"N Engl J Med"},{"key":"2021122209455718400_R51","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/(SICI)1097-0142(19961015)78:8<1838::AID-CNCR27>3.0.CO;2-Y","article-title":"The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age","volume":"78","author":"Winchester","year":"1996","journal-title":"Cancer"},{"key":"2021122209455718400_R52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3","article-title":"Younger women with breast carcinoma have a poorer prognosis than older women","volume":"77","author":"Chung","year":"1996","journal-title":"Cancer"},{"key":"2021122209455718400_R53","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/oxfordjournals.annonc.a058976","article-title":"The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up","volume":"5","author":"Castiglione-Gertsch","year":"1994","journal-title":"Ann Oncol"},{"key":"2021122209455718400_R54","first-page":"67a","article-title":"Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomized trial by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the South-East Sweden Breast Cancer Group, Stockholm Breast Cancer Study Group, and the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (GIVIO)","volume":"18","author":"Rutzvist","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209455718400_R55","first-page":"30","article-title":"Adjuvant treatment of premenopausal breast cancer with Zoladex and tamoxifen","volume":"57","author":"Baum","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209455718400_R56","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0960-9776(16)30022-4","article-title":"Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93","volume":"10","author":"International Breast Cancer Study Group","year":"2001","journal-title":"Breast"},{"key":"2021122209455718400_R57","first-page":"14a","article-title":"Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy","volume":"22","author":"Arriagada","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209455718400_R58","first-page":"15a","article-title":"Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101)","volume":"22","author":"Davidson","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209455718400_R59","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/jnci\/djg119","article-title":"Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial","volume":"95","author":"Castiglione-Gertsch","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2021122209455718400_R60","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1998","journal-title":"Lancet"},{"key":"2021122209455718400_R61","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1200\/JCO.2002.08.169","article-title":"Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer","volume":"20","author":"Love","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209455718400_R62","first-page":"16a","article-title":"Phase III comparison of tamoxifen with ovarian ablation in premenopausal women with axillary node negative receptor positive breast cancer &lt;3 cm","volume":"22","author":"Robert","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209455718400_R63","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2000.18.14.2718","article-title":"Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-\/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial","volume":"18","author":"Boccardo","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122209455718400_R64","first-page":"72a","article-title":"Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients with positive hormone-receptor (HR+) and 1\u20133 node-positive (N+) tumor, results of the FASG 06 trial","volume":"19","author":"Roche","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209455718400_R65","first-page":"117","article-title":"Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node and receptor positive breast cancer patients: a randomized trial with a 7 years median follow-up","volume":"15","author":"Roche","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209455718400_R66","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/oxfordjournals.jncimonographs.a003460","article-title":"National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1\u20133, 2000","volume":"30","author":"National Institutes of Health Consensus Development Panel","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2021122209455718400_R67","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2003.04.576","article-title":"Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer","volume":"21","author":"Goldhirsch","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.9-5-507","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.9-5-507","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/5\/507\/41844646\/oncolo_9_5_507.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/5\/507\/41844646\/oncolo_9_5_507.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:27:29Z","timestamp":1640194049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/9\/5\/507\/6387977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,1]]},"references-count":67,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2004,9,1]]},"published-print":{"date-parts":[[2004,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.9-5-507","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2004,9,1]]},"published":{"date-parts":[[2004,9,1]]}}}